Moreover, given that our pathway analyses highlighted the involvement of the melanin metabolic and biosynthetic process in BCC pathogenesis, drugs targeting genes (i.e., TRPC1, SLC45A2, TYRP1, TYR, PMEL, DCT, OCA2, MYO5A, MC1R, CTNS, ASIP, DDT, and BCL2) involved in those pathways could be potential therapies for BCC. This evidence concerns the gene TYRP1 and skin basal cell carcinoma.